Evolving trends and drug class dynamics in drug-induced fatty liver disease over two decades
en-GBde-DEes-ESfr-FR

Evolving trends and drug class dynamics in drug-induced fatty liver disease over two decades

16/12/2025 Frontiers Journals
Drug-induced fatty liver disease (DIFLD) is increasingly recognized as a critical adverse drug reaction, with potential progression to liver fibrosis, cirrhosis, and liver failure. Using FAERS reports from 2004 to 2023, the study analyzed trends in steatotic liver disease (SLD) and liver failure associated with various drugs, stratifying by therapeutic class, age, sex, and region.

A total of 15,269 SLD cases were reported, rising from 481 in 2004 to 1,413 in 2023, with adults aged 18–64 and females being the most affected populations. Monoclonal antibodies (MAbs), antipsychotics, and disease-modifying antirheumatic drugs (DMARDs) were the most frequently implicated drug classes, with MAbs showing the fastest increase in cases (+11.77/year). Adalimumab was the single drug most often associated with DIFLD (5.81%). Regional differences were observed, with the U.S. reporting 45.44% of cases.

This work provides a comprehensive overview of evolving drug-related risk patterns in DIFLD, emphasizing the importance of pharmacovigilance, demographic awareness, and targeted preventive strategies to optimize patient safety.
DOI:10.20517/mtod.2025.78
https://dx.doi.org/10.20517/mtod.2025.78
Attached files
  • 59789871.png
16/12/2025 Frontiers Journals
Regions: Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement